Acceleron Pharma Inc. (NASDAQ:XLRN) has been given an average recommendation of “Buy” by the eleven analysts that are currently covering the company. Two equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $44.50.

Several equities research analysts recently issued reports on XLRN shares. Morgan Stanley reiterated a “buy” rating and issued a $58.00 price objective on shares of Acceleron Pharma in a report on Friday, August 5th. FBR & Co reiterated a “buy” rating and issued a $63.00 price objective on shares of Acceleron Pharma in a report on Friday, August 5th. BTIG Research started coverage on Acceleron Pharma in a report on Friday, August 19th. They issued a “buy” rating and a $46.00 price objective on the stock. Credit Suisse Group AG reiterated a “buy” rating and issued a $42.00 price objective on shares of Acceleron Pharma in a report on Wednesday, September 28th. Finally, Citigroup Inc. started coverage on Acceleron Pharma in a report on Thursday, September 29th. They issued a “neutral” rating and a $40.00 price objective on the stock.

In other news, Director Jean George sold 857,145 shares of the business’s stock in a transaction dated Friday, September 30th. The stock was sold at an average price of $35.50, for a total value of $30,428,647.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John D. Quisel sold 45,952 shares of the business’s stock in a transaction dated Wednesday, September 21st. The shares were sold at an average price of $38.05, for a total value of $1,748,473.60. Following the completion of the sale, the senior vice president now directly owns 77,004 shares of the company’s stock, valued at $2,930,002.20. The disclosure for this sale can be found here. Insiders own 12.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC increased its stake in Acceleron Pharma by 1.0% in the second quarter. Parametric Portfolio Associates LLC now owns 8,797 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 90 shares during the last quarter. Legal & General Group Plc increased its stake in Acceleron Pharma by 4.3% in the second quarter. Legal & General Group Plc now owns 4,214 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 173 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Acceleron Pharma by 1.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 18,078 shares of the biopharmaceutical company’s stock valued at $614,000 after buying an additional 185 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in Acceleron Pharma by 0.6% in the second quarter. Mutual of America Capital Management LLC now owns 44,663 shares of the biopharmaceutical company’s stock valued at $1,518,000 after buying an additional 250 shares during the last quarter. Finally, Tocqueville Asset Management L.P. increased its stake in Acceleron Pharma by 2.2% in the second quarter. Tocqueville Asset Management L.P. now owns 19,750 shares of the biopharmaceutical company’s stock valued at $671,000 after buying an additional 425 shares during the last quarter. 79.32% of the stock is owned by institutional investors and hedge funds.

Shares of Acceleron Pharma (NASDAQ:XLRN) opened at 37.96 on Wednesday. The firm has a 50-day moving average price of $31.91 and a 200-day moving average price of $32.90. The stock’s market capitalization is $1.43 billion. Acceleron Pharma has a 1-year low of $22.67 and a 1-year high of $50.86.

Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Acceleron Pharma had a negative net margin of 229.77% and a negative return on equity of 30.75%. The business earned $3 million during the quarter, compared to analysts’ expectations of $4.08 million. On average, equities research analysts forecast that Acceleron Pharma will post ($1.58) earnings per share for the current year.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia.

5 Day Chart for NASDAQ:XLRN

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.